Resumen
Inhibidores orales directos de la trombina o inhibidores orales del factor Xa frente a anticoagulantes convencionales para el tratamiento de la trombosis venosa profunda: una revisión Cochrane
Xiaoqin Wang11, Yanfang Ma2, Xu Hui3,4, Meixuan Li3,4, Jing Li3,4, Jinhui Tian3,4, Qi Wang5, Peijing Yan6, Jianfeng Li7, Ping Xie7, Kehu Yang3,4, Liang Yao5
Filiación de los autores
1Michael G DeGroote Institute for Pain Research and Care, McMaster University, Hamilton, Canadá. 2School of Chinese Medicine, Hong Kong Baptist University, Hong Kong Special Administrative Region, China. 3Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China. 4Evidence-Based Social Science Research Center, School of Public Health, Lanzhou University, Lanzhou, China. 5Department of Health Research Methods, Evidence and Impact, Faculty of Health Sciences, McMaster University, Hamilton, Canadá. 6Department of Epidemiology and Health Statistics, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, China. 7Department of Cardiology, Gansu Provincial Hospital, Lanzhou, China.
DOI
Cita
Wang X, Ma Y, Hui X, Li M, Li J, Tian J, et al. Inhibidores orales directos de la trombina o inhibidores orales del factor Xa frente a anticoagulantes convencionales para el tratamiento de la trombosis venosa profunda: revisión Cochrane. Emergencias. ;:-